By Jeff Overley ( February 5, 2016, 8:15 PM EST) -- Amgen is urging the Federal Circuit to rule that biosimilar makers must always give 180-day advance notice of sales to brand-name rivals, arguing that nothing in the Affordable Care Act's approval pathway allows for exceptions, according to a brief released Friday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.